|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTLL3 |
Gene summary for TTLL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTLL3 | Gene ID | 26140 |
| Gene name | tubulin tyrosine ligase like 3 | |
| Gene Alias | HOTTL | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | J3KQB2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26140 | TTLL3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.14e-03 | 2.21e-01 | 0.0155 |
| 26140 | TTLL3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.01e-04 | 2.91e-01 | -0.0811 |
| 26140 | TTLL3 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.57e-10 | 4.49e-01 | -0.1088 |
| 26140 | TTLL3 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.41e-10 | 3.35e-01 | -0.1954 |
| 26140 | TTLL3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.08e-04 | 3.31e-01 | -0.1207 |
| 26140 | TTLL3 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.36e-13 | 3.79e-01 | -0.1464 |
| 26140 | TTLL3 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.00e-24 | 6.29e-01 | -0.1001 |
| 26140 | TTLL3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.15e-14 | 4.95e-01 | -0.059 |
| 26140 | TTLL3 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.19e-08 | 2.96e-01 | 0.096 |
| 26140 | TTLL3 | HTA11_10623_2000001011 | Human | Colorectum | AD | 4.32e-02 | 3.04e-01 | -0.0177 |
| 26140 | TTLL3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.71e-10 | 4.66e-01 | 0.0338 |
| 26140 | TTLL3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.64e-15 | 4.22e-01 | 0.0674 |
| 26140 | TTLL3 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.73e-08 | 5.29e-01 | 0.0112 |
| 26140 | TTLL3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.68e-04 | 2.14e-01 | 0.294 |
| 26140 | TTLL3 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.34e-09 | 4.44e-01 | 0.281 |
| 26140 | TTLL3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.36e-09 | 3.45e-01 | 0.3859 |
| 26140 | TTLL3 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.77e-03 | 3.62e-01 | 0.2585 |
| 26140 | TTLL3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.57e-20 | 4.90e-01 | 0.3005 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTLL3 | SNV | Missense_Mutation | c.1955C>T | p.Thr652Ile | p.T652I | protein_coding | tolerated(0.3) | possibly_damaging(0.451) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| TTLL3 | SNV | Missense_Mutation | rs748481534 | c.749N>T | p.Gly250Val | p.G250V | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0H0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TTLL3 | SNV | Missense_Mutation | rs777804808 | c.1603N>T | p.Arg535Trp | p.R535W | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTLL3 | SNV | Missense_Mutation | c.1644N>C | p.Gln548His | p.Q548H | protein_coding | tolerated(0.14) | benign(0.037) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | ||
| TTLL3 | SNV | Missense_Mutation | c.2076N>A | p.Met692Ile | p.M692I | protein_coding | tolerated(0.2) | benign(0.012) | TCGA-GM-A2DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| TTLL3 | SNV | Missense_Mutation | rs751777696 | c.1180G>A | p.Asp394Asn | p.D394N | protein_coding | tolerated(0.23) | benign(0.03) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TTLL3 | SNV | Missense_Mutation | novel | c.1402N>A | p.Glu468Lys | p.E468K | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| TTLL3 | SNV | Missense_Mutation | c.443N>A | p.Arg148Lys | p.R148K | protein_coding | tolerated(0.61) | benign(0.026) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| TTLL3 | SNV | Missense_Mutation | rs540084396 | c.2617G>A | p.Ala873Thr | p.A873T | protein_coding | tolerated_low_confidence(0.44) | benign(0.003) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TTLL3 | SNV | Missense_Mutation | novel | c.1949G>A | p.Cys650Tyr | p.C650Y | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |